thymidine has been researched along with 1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, E; Boyer, PL; Ding, J; Hughes, SH | 1 |
| Balzarini, J; Camarasa, MJ; De Clercq, E; Karlsson, A; Pérez-Pérez, MJ; San-Félix, A; Vélazquez, S | 1 |
| Balzarini, J; Bohman, C; Camarasa, MJ; De Clercq, E; Naesens, L; Pérez-Pérez, MJ; San-Félix, A | 1 |
| Anné, J; Balzarini, J; De Clercq, E; De Vreese, K; Debyser, Z; Desmyter, J; Jonckheere, H; Vandekerckhove, J | 1 |
| Alvarez, R; Balzarini, J; Camarasa, MJ; Gago, F; Jimeno, ML; Pérez-Pérez, MJ | 1 |
| Aquaro, S; Balzarini, J; Camarasa, MJ; Cenci, A; Clotet, B; De Clercq, E; Desmyter, J; Esnouf, RM; Hermans, P; Pelemans, H; Pérez-Pérez, MJ; Perno, CF; Ruiz, L; Schmit, JC; Sprecher, S; Van Laethem, K; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM; Witvrouw, M | 1 |
| Aertsen, A; Balzarini, J; Camarasa, MJ; De Clercq, E; Pelemans, H; Pérez-Pérez, MJ; San-Félix, A; Van Laethem, K; Vandamme, AM; Velázquez, S | 1 |
| Anderson, JN; Balzarini, J; Camarasa, MJ; De Clercq, E; Karlsson, A; Pérez-Pérez, MJ; Perno, CF; San-Félix, A; Velázquez, S | 1 |
| Camarasa, MJ; Pérez-Pérez, MJ; San-Félix, A; Velázquez, S | 1 |
1 review(s) available for thymidine and 1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)
| Article | Year |
|---|---|
TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization.
Topics: Anti-HIV Agents; Dimerization; HIV Reverse Transcriptase; Humans; Organosilicon Compounds; Reverse Transcriptase Inhibitors; Spiro Compounds; Thymidine; Uridine | 2005 |
8 other study(ies) available for thymidine and 1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)
| Article | Year |
|---|---|
Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Antiviral Agents; Benzodiazepines; Drug Resistance, Microbial; HIV Reverse Transcriptase; Imidazoles; Macromolecular Substances; Mutation; Plasmids; Protein Conformation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Spiro Compounds; Substrate Specificity; Thymidine | 1994 |
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).
Topics: Antiviral Agents; Base Sequence; Carboxin; Cell Line; Delavirdine; DNA Primers; Drug Antagonism; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Molecular Sequence Data; Mutation; Piperazines; Reverse Transcriptase Inhibitors; Spiro Compounds; Thymidine | 1995 |
Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3-N- methyl-thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dio xide).
Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Line; Half-Life; HIV-1; Humans; Metabolic Clearance Rate; Mice; Models, Chemical; Spiro Compounds; Thymidine; Thymidine Kinase; Thymidine Phosphorylase; Tissue Distribution; Tritium; Uridine | 1993 |
A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1.
Topics: Benzodiazepines; Deoxyguanine Nucleotides; Dideoxynucleotides; Escherichia coli; Gene Expression; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Mass Spectrometry; Plasmids; Recombinant Fusion Proteins; Reverse Transcriptase Inhibitors; Spiro Compounds; Thymidine; Virion | 1996 |
Novel 3'-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations.
Topics: Anti-HIV Agents; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Structure; Nucleosides; Reverse Transcriptase Inhibitors; Spiro Compounds; Static Electricity; Thymidine; Uridine | 1998 |
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Topics: Anti-HIV Agents; Base Sequence; DNA Primers; Drug Resistance, Microbial; Genes, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Phenotype; Point Mutation; Protein Conformation; Reverse Transcriptase Inhibitors; Spiro Compounds; Thymidine | 2000 |
Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Topics: Alanine; Anti-HIV Agents; Aspartic Acid; Cell Line; Deoxyguanine Nucleotides; Dideoxynucleotides; DNA-Directed DNA Polymerase; Glutamic Acid; Glutamine; HIV Reverse Transcriptase; HIV-1; Humans; Lysine; Mutagenesis, Site-Directed; Nucleosides; Phenylalanine; Recombination, Genetic; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Spiro Compounds; Thymidine; Tyrosine; Uridine | 2001 |
Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.
Topics: Anti-HIV Agents; Antimetabolites; Deoxycytosine Nucleotides; Drug Resistance, Microbial; Genome, Viral; HIV Reverse Transcriptase; HIV-1; Reverse Transcriptase Inhibitors; Spiro Compounds; Thymidine; Thymine Nucleotides; Uridine | 2001 |